Gilead Sciences (GILD) : Oakbrook Investments scooped up 53,370 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 22, 2016. The investment management firm now holds a total of 390,440 shares of Gilead Sciences which is valued at $33,792,582.Gilead Sciences makes up approximately 1.81% of Oakbrook Investments’s portfolio.
Other Hedge Funds, Including , Bender Robert Associates reduced its stake in GILD by selling 1,477 shares or 1.46% in the most recent quarter. The Hedge Fund company now holds 100,020 shares of GILD which is valued at $8,656,731. Gilead Sciences makes up approx 5.78% of Bender Robert Associates’s portfolio.Willingdon Wealth Management boosted its stake in GILD in the latest quarter, The investment management firm added 1,389 additional shares and now holds a total of 10,917 shares of Gilead Sciences which is valued at $944,866. Gilead Sciences makes up approx 0.47% of Willingdon Wealth Management’s portfolio.Ferguson Wellman Capital Management Inc reduced its stake in GILD by selling 131,036 shares or 30.42% in the most recent quarter. The Hedge Fund company now holds 299,773 shares of GILD which is valued at $26,059,267. Gilead Sciences makes up approx 1.06% of Ferguson Wellman Capital Management Inc’s portfolio. Warren Averett Asset Management sold out all of its stake in GILD during the most recent quarter. The investment firm sold 2,578 shares of GILD which is valued $221,064.Firstmerit Bank N A Trustee boosted its stake in GILD in the latest quarter, The investment management firm added 134 additional shares and now holds a total of 3,775 shares of Gilead Sciences which is valued at $323,706. Gilead Sciences makes up approx 0.03% of Firstmerit Bank N A Trustee’s portfolio.
Gilead Sciences closed down -1.77 points or -2.18% at $79.47 with 1,94,65,672 shares getting traded on Friday. Post opening the session at $80.6, the shares hit an intraday low of $79.37 and an intraday high of $80.84 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Gilead Sciences reported $3.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Jul 25, 2016. Analyst had a consensus of $3.01. The company had revenue of $7776.00 million for the quarter, compared to analysts expectations of $7795.08 million. The company’s revenue was down -5.7 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $3.15 EPS.
Many Wall Street Analysts have commented on Gilead Sciences. Gilead Sciences was Downgraded by Argus to ” Hold” on Jul 29, 2016. Shares were Reiterated by RBC Capital Mkts on Jul 26, 2016 to “Outperform” and Lowered the Price Target to $ 105 from a previous price target of $120 .Gilead Sciences was Downgraded by Needham to ” Hold” on Jul 26, 2016.
Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Companys primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Companys HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Companys oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.